Literature DB >> 25858541

The Nurr1 Activator 1,1-Bis(3'-Indolyl)-1-(p-Chlorophenyl)Methane Blocks Inflammatory Gene Expression in BV-2 Microglial Cells by Inhibiting Nuclear Factor κB.

Briana R De Miranda1, Katriana A Popichak1, Sean L Hammond1, Bryce A Jorgensen1, Aaron T Phillips1, Stephen Safe1, Ronald B Tjalkens2.   

Abstract

NR4A family orphan nuclear receptors are an important class of transcription factors for development and homeostasis of dopaminergic neurons that also inhibit expression of inflammatory genes in glial cells. The identification of NR4A2 (Nurr1) as a suppressor of nuclear factor κB (NF-κB)-related neuroinflammatory genes in microglia and astrocytes suggests that this receptor could be a target for pharmacologic intervention in neurologic disease, but compounds that promote this activity are lacking. Selected diindolylmethane compounds (C-DIMs) have been shown to activate or inactivate nuclear receptors, including Nurr1, in cancer cells and also suppress astrocyte inflammatory signaling in vitro. Based upon these data, we postulated that C-DIM12 [1,1-bis(3'-indolyl)-1-(p-chlorophenyl) methane] would suppress inflammatory signaling in microglia by a Nurr1-dependent mechanism. C-DIM12 inhibited lipopolysaccharide (LPS)-induced expression of NF-κB-regulated genes in BV-2 microglia including nitric oxide synthase (NOS2), interleukin-6 (IL-6), and chemokine (C-C motif) ligand 2 (CCL2), and the effects were attenuated by Nurr1-RNA interference. Additionally, C-DIM12 decreased NF-κB activation in NF-κB-GFP (green fluorescent protein) reporter cells and enhanced nuclear translocation of Nurr1 primary microglia. Chromatin immunoprecipitation assays indicated that C-DIM12 decreased lipopolysaccharide-induced p65 binding to the NOS2 promoter and concurrently enhanced binding of Nurr1 to the p65-binding site. Consistent with these findings, C-DIM12 also stabilized binding of the Corepressor for Repressor Element 1 Silencing Transcription Factor (CoREST) and the Nuclear Receptor Corepressor 2 (NCOR2). Collectively, these data identify C-DIM12 as a modulator of Nurr1 activity that results in inhibition of NF-κB-dependent gene expression in glial cells by stabilizing nuclear corepressor proteins, which reduces binding of p65 to inflammatory gene promoters.
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25858541      PMCID: PMC4429718          DOI: 10.1124/mol.114.095398

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  34 in total

Review 1.  Microglia and neuroprotection: from in vitro studies to therapeutic applications.

Authors:  Elisabetta Polazzi; Barbara Monti
Journal:  Prog Neurobiol       Date:  2010-07-04       Impact factor: 11.685

2.  Activation of nuclear TR3 (NR4A1) by a diindolylmethane analog induces apoptosis and proapoptotic genes in pancreatic cancer cells and tumors.

Authors:  Kyungsil Yoon; Syng-Ook Lee; Sung-Dae Cho; Kyounghyun Kim; Shaheen Khan; Stephen Safe
Journal:  Carcinogenesis       Date:  2011-03-01       Impact factor: 4.944

3.  Activation of nerve growth factor-induced B alpha by methylene-substituted diindolylmethanes in bladder cancer cells induces apoptosis and inhibits tumor growth.

Authors:  Sung Dae Cho; Syng-Ook Lee; Sudhakar Chintharlapalli; Maen Abdelrahim; Shaheen Khan; Kyungsil Yoon; Ashish M Kamat; Stephen Safe
Journal:  Mol Pharmacol       Date:  2009-12-18       Impact factor: 4.436

Review 4.  Targeting NR4A1 (TR3) in cancer cells and tumors.

Authors:  Syng-Ook Lee; Xi Li; Shaheen Khan; Stephen Safe
Journal:  Expert Opin Ther Targets       Date:  2011-01-05       Impact factor: 6.902

Review 5.  Future directions for immune modulation in neurodegenerative disorders: focus on Parkinson's disease.

Authors:  Kathleen A Maguire-Zeiss; Howard J Federoff
Journal:  J Neural Transm (Vienna)       Date:  2010-06-12       Impact factor: 3.575

Review 6.  Mechanisms underlying inflammation in neurodegeneration.

Authors:  Christopher K Glass; Kaoru Saijo; Beate Winner; Maria Carolina Marchetto; Fred H Gage
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

Review 7.  NR4A orphan nuclear receptors: transcriptional regulators of gene expression in metabolism and vascular biology.

Authors:  Yue Zhao; Dennis Bruemmer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-08       Impact factor: 8.311

8.  A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death.

Authors:  Kaoru Saijo; Beate Winner; Christian T Carson; Jana G Collier; Leah Boyer; Michael G Rosenfeld; Fred H Gage; Christopher K Glass
Journal:  Cell       Date:  2009-04-03       Impact factor: 41.582

9.  NGFI-B nuclear orphan receptor Nurr1 interacts with p53 and suppresses its transcriptional activity.

Authors:  Tao Zhang; Pingping Wang; Haigang Ren; Jun Fan; Guanghui Wang
Journal:  Mol Cancer Res       Date:  2009-08-11       Impact factor: 5.852

Review 10.  Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention.

Authors:  Malú G Tansey; Matthew S Goldberg
Journal:  Neurobiol Dis       Date:  2009-11-10       Impact factor: 5.996

View more
  37 in total

Review 1.  Structure-dependent activation of gene expression by bis-indole and quinoline-derived activators of nuclear receptor 4A2.

Authors:  Xi Li; Ronald B Tjalkens; Rupesh Shrestha; Stephen Safe
Journal:  Chem Biol Drug Des       Date:  2019-07-21       Impact factor: 2.817

Review 2.  Transcriptional control of microglia phenotypes in health and disease.

Authors:  Inge R Holtman; Dylan Skola; Christopher K Glass
Journal:  J Clin Invest       Date:  2017-07-31       Impact factor: 14.808

3.  Chronic Neuroinflammation Induced by Lipopolysaccharide Injection into the Third Ventricle Induces Behavioral Changes.

Authors:  Shufang Na; Xuejiao Duan; Rongyan Wang; Yanjie Fan; Ke Xue; Shuwei Tian; Zheqiong Yang; Ke Li; Jiang Yue
Journal:  J Mol Neurosci       Date:  2021-01-06       Impact factor: 3.444

Review 4.  Nurr1-Based Therapies for Parkinson's Disease.

Authors:  Jie Dong; Song Li; Jing-Lin Mo; Huai-Bin Cai; Wei-Dong Le
Journal:  CNS Neurosci Ther       Date:  2016-03-25       Impact factor: 5.243

5.  4-amino-7-chloroquinoline derivatives for treating Parkinson's disease: implications for drug discovery.

Authors:  Chun-Hyung Kim; Pierre Leblanc; Kwang-Soo Kim
Journal:  Expert Opin Drug Discov       Date:  2016-03-07       Impact factor: 6.098

6.  Activation of Peroxisome Proliferator-Activated Receptor-α Increases the Expression of Nuclear Receptor Related 1 Protein (Nurr1) in Dopaminergic Neurons.

Authors:  Carl G Gottschalk; Avik Roy; Malabendu Jana; Madhuchhanda Kundu; Kalipada Pahan
Journal:  Mol Neurobiol       Date:  2019-05-24       Impact factor: 5.590

Review 7.  The multi-faceted role of retinoid X receptor in bone remodeling.

Authors:  María P Menéndez-Gutiérrez; Mercedes Ricote
Journal:  Cell Mol Life Sci       Date:  2017-01-19       Impact factor: 9.261

8.  A novel diindolylmethane analog, 1,1-bis(3'-indolyl)-1-(p-chlorophenyl) methane, inhibits the tumor necrosis factor-induced inflammatory response in primary murine synovial fibroblasts through a Nurr1-dependent mechanism.

Authors:  Maryam F Afzali; Katriana A Popichak; Lindsey H Burton; Anna L Klochak; William J Wilson; Stephen Safe; Ronald B Tjalkens; Marie E Legare
Journal:  Mol Immunol       Date:  2018-06-02       Impact factor: 4.407

9.  A novel synthetic activator of Nurr1 induces dopaminergic gene expression and protects against 6-hydroxydopamine neurotoxicity in vitro.

Authors:  Sean L Hammond; Stephen Safe; Ronald B Tjalkens
Journal:  Neurosci Lett       Date:  2015-09-14       Impact factor: 3.046

10.  Anesthetic isoflurane attenuates activated microglial cytokine-induced VSC4.1 motoneuronal apoptosis.

Authors:  Shuangmei Yang; Jun Liu; Xiaoran Zhang; Jianmin Tian; Zhichao Zuo; Jingjing Liu; Xiuqin Yue
Journal:  Am J Transl Res       Date:  2016-03-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.